Abstract

Dipeptidyl-peptidase IV (DPP4), originally identified as an aminopeptidase in 1960s, is an ubiquitously expressed protease presented as either a membrane-bound or soluble form. DPP4 cleaves dipeptide off from the N-terminal of its substrates, altering the bioactivity of its substrates. Subsequent studies reveal that DPP4 is also involved in various cellular processes by directly binding to a number of ligands, including adenosine deaminase, CD45, fibronectin, plasminogen, and caveolin-1. In recent years, many novel functions of DPP4, such as promoting fibrosis and mediating virus entry, have been discovered. Due to its implication in fibrotic response and immunoregulation, increasing studies are focusing on the potential role of DPP4 in inflammatory disorders. As a moonlighting protein, DPP4 possesses multiple functions in different types of cells, including both enzymatic and non-enzymatic functions. However, most of the review articles on the role of DPP4 in autoimmune disease were focused on the association between DPP4 enzymatic inhibitors and the risk of autoimmune disease. An updated comprehensive summary of DPP4’s immunoregulatory actions including both enzymatic dependent and independent functions is needed. In this article, we will review the recent advances of DPP4 in immune regulation and autoimmune rheumatic disease.

Highlights

  • Dipeptidyl-peptidase IV (DPP4), known as CD26, was first discovered as a protease in 1966 [1]

  • This review focuses on emerging evidence of DPP4 in immune regulation and attempts to build a bridge between DPP4 and autoimmune diseases

  • Since the synovial level of Stromal cell-derived factor-1 (SDF-1) was strongly correlated with the disease activity score (DAS28 CRP) and inflammation markers [109, 110], the decrease of synovial DPP4 in Rheumatoid arthritis (RA) may lead to synovial inflammation via SDF-1/ CXCR4 axis. These results indicate a critical role of DPP4/SDF1/ CXCR4 in synovial inflammation in RA

Read more

Summary

Introduction

Dipeptidyl-peptidase IV (DPP4), known as CD26, was first discovered as a protease in 1966 [1]. The expression level of DPP4 is associated with the activation status of immune cells. Another study suggested that the expression of DPP4 in the skin fibroblast was upregulated in patients with systemic sclerosis compared with that of healthy individuals.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.